A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)

• Status: Terminated
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The clinical study will evaluate safety, tolerability and Pharmacokinetics of MK0683 in combination with carboplatin and paclitaxel in chemotherapy-naive NSCLC patients.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Carboplatin; Paclitaxel; Vorinostat

Criteria

Inclusion Criteria:

• Chemotherapy-naive patients who are histologically or cytologically diagnosed NSCLC with stage IIIB (not applicable of radical thoracic radiation) or stage IV

• Patients with normal organ function and bone marrow function

Exclusion Criteria:

• Given radical thoracic radiation for NSCLC or radiation for other than original lesion within 3 weeks

• Any peripheral neuropathy above grade 2

• Any ascites, pleural effusion or pericardiac effusion which requires treatment

• Any uncontrolled concomitant illness

• Pregnant or breast-feeding